Posted by Michael Wonder on 17 Aug 2021
Novartis secures new approval in China for Cosentyx (secukinumab) in paediatric psoriasis
17 August 2021 - China NMPA approval reinforces that Cosentyx (secukinumab) is safe and effective for children and adults with psoriasis.
Novartis today announced that the China National Medical Products Administration has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (six years and older with a body weight ≥50 kg) who are candidates for systemic therapy or phototherapy, making it the only interleukin inhibitor approved in China for these patients.
